Research on the comparison of the demethylvancomycin’s diffusion–deposition characteristics in the ocular solid tissues of sustained subtenon drug delivery with subconjunctival injection

References

• Agard E, Elchehab H, Ract-Madoux G, et al. (2015). Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol 50:127–31
   PubMed Web of Science ®Google Scholar
• Ahmed I. (2003) The noncorneal route in ocular drug delivery. In: Mitra AK, ed. Ophthalmic drug delivery systems. New York: Marcel Dekker, 335–63
   Google Scholar
• Ambati J, Canakis CS, Miller JW, et al (2000). Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 41:1181–5
   PubMed Web of Science ®Google Scholar
• Anderson OA, Jackson TL, Singh JK, et al. (2008). Human transscleral albumin permeability and the effect of topographical location and donor age. Invest Ophthalmol Vis Sci 49: 4041–5
   PubMed Web of Science ®Google Scholar
• Barar J, Javadzadeh AR, Omidi Y. (2008). Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv 5:567–81
   PubMed Web of Science ®Google Scholar
• Borcherding MS, Blacik LJ, Sittig RA, et al. (1975). Proteoglycans and collagen fibre organization in human corneoscleral tissue. Exp Eye Res 21:59–70
   PubMed Web of Science ®Google Scholar
• Bourges JL, Bloquel C, Thomas A, et al. (2006). Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 58:1182–202
   PubMed Web of Science ®Google Scholar
• Cristina I, Kimia Z, George M, et al. (2012). Endophthalmitis following intravitreal injections. Graefe's Archive for Clinical and Experimental Ophthalmology 250:499–505
   PubMed Web of Science ®Google Scholar
• Cruysberg LP, Franklin AJ, Sanders J, et al. (2005). Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2). Retina (Philadelphia, PA) 25:1022–31
   PubMed Web of Science ®Google Scholar
• Gupta H, Jain S, Mathur R, et al. (2007). Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv 14:507–15
   PubMed Web of Science ®Google Scholar
• Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. (2005). Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 57:2010–32
   PubMed Web of Science ®Google Scholar
• Janoria KG, Gunda S, Boddu SH, Mitra AK. (2007). Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4:371–88
   PubMed Web of Science ®Google Scholar
• Hunt AH, Vernon PD. (1981). Complexation of acetyl-d-alanyl-d-alanine by antibiotic A35512B. J Antibiot (Tokyo) 34:469–71
   PubMed Web of Science ®Google Scholar
• Kalam MA, Alshamsan A, Aljuffali IA, et al. (2016). Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Drug Deliv 23:896–907
   PubMed Web of Science ®Google Scholar
• Kau JC, Geroski DH, Edelhauser HF. (2005). Transscleral permeability of fluorescent-labeled antibiotics. J Ocul Pharmacol Ther 21:1–10
   PubMed Web of Science ®Google Scholar
• Li N, Zhuang CY, Wang M, et al. (2012). Low molecular weight chitosan-coated liposomes for ocular drug delivery: in vitro and in vivo studies. Drug Deliv 19:28–35
   PubMed Web of Science ®Google Scholar
• Mathurm M, Gilhotra RM. (2011). Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E2-induced ocular inflammation. Drug Deliv 18:54–64
   PubMed Web of Science ®Google Scholar
• Nagarajan R. (1993). Structure–activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot 46:1181–95
   PubMed Web of Science ®Google Scholar
• Okabe J, Kimura H, Kunou N, et al. (2003). Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 44: 740–4
   PubMed Web of Science ®Google Scholar
• Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. (1998). Human sclera: thickness and surface area. Am J Ophthalmol 125:237–41
   PubMed Web of Science ®Google Scholar
• Penha FM, Rodrigues EB, Furlani BA, et al. (2011). Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol 7:1021–34
   PubMed Web of Science ®Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. (2004). Cationic vectors in ocular drug delivery. J Drug Target 12:623–33
   PubMed Web of Science ®Google Scholar
• Ranta VP, Urtti A. (2006). Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 58:1164–81
   PubMed Web of Science ®Google Scholar
• Robinson JR. (1993) Ocular anatomy and physiology relevant to ocular drug delivery. In: Mitra AK, ed. Ophthalmic drug delivery systems. Marcel Dekker: New York, 29–57
   Google Scholar
• Shuler RK, Dioguardi PK, Henjy C, et al. (2004). Scleral permeability of a small, single-stranded oligonucleotide. J Ocul Pharmacol Ther 20:159–68
   PubMed Web of Science ®Google Scholar
• Urtti A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–5
   PubMed Web of Science ®Google Scholar
• Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. (2008). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81–7
   PubMed Web of Science ®Google Scholar
• Yan H, Zhao Q, Yuan J, et al. (2000). Affinity adsorbents for the vancomycin group of antibiotics. Biotechnol Appl Biochem 31: 15–20
   PubMed Web of Science ®Google Scholar
• Yousry C, Fahmy RH, Essam T, et al. (2016). Nanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluation. Drug Dev Ind Pharm 19:1–11
   Google Scholar